Chemotherapy resistance in metastatic breast cancer: The evolving role of ixabepilone

Abstract

Resistance to chemotherapy is a major obstacle to the eff ective treatment of many tumor types. Although many anticancer therapies can alter tumor growth, in most cases the eff ect is not long lasting. Consequently, there is a signifi cant need for new agents with low susceptibility to common drug resistance mechanisms in order to improve response rates and potentially extend survival. Approximately 30% of the women diagnosed with early-stage disease in turn progress to metastatic breast cancer, for which therapeutic options are limited. Current recommendations for fi rst-line chemotherapy include anthracycline-based regimens and taxanes (paclitaxel and docetaxel). They typically give response rates of 30 to 70% but the responses are often not durable, with a time to progression of 6 to 10 months. Patients with progression or resistance may be administered capecitabine, gemcitabine, vinorelbine, albumin-bound paclitaxel, or ixabepilone, while other drugs are being evaluated. Response rates in this setting tend to be low (20 to 30%); the median duration of responses is <6 months and the results do not always translate into improved longterm outcomes. The present article reviews treatment options in taxane-resistant metastatic breast cancer and the role of ixabepilone in this setting. © 2010 Rivera and Gomez; licensee BioMed Central Ltd.